Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.78 |
| ▸ | MEN1 | O00255 | 2/20 | 0.78 |
| ▸ | CA2 | P00918 | 7/20 | 0.67 |
| ▸ | CA1 | P00915 | 6/20 | 0.67 |
| ▸ | CA9 | Q16790 | 4/20 | 0.67 |
| ▸ | STS | P08842 | 1/20 | 0.66 |
| ▸ | CA12 | O43570 | 4/20 | 0.64 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | MAOA | P21397 | 1/20 | 0.62 |
| ▸ | CA7 | P43166 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | ESR1 | P03372 | 1/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28791529 | 0.91 | KMT2A (0.80) | KMT2AMEN1CA2CA1CA9 | |
| SCHEMBL25311401 | 0.86 | STS (0.68) | KMT2AMEN1CA2CA1CA9 | |
| Ethyl Benzoate SCHEMBL29187656 | 0.86 | LMNA (0.64) | KMT2AMEN1CA2CA1CA9 | |
| SCHEMBL9417503 | 0.85 | KMT2A (0.66) | KMT2AMEN1CA2CA1CA9 | |
| SCHEMBL29504635 | 0.84 | CA1 (0.79) | KMT2AMEN1CA2CA1CA9 | |
| SCHEMBL63779 | 0.84 | KMT2A (0.64) | KMT2AMEN1CA2CA1CA9 | |
| SCHEMBL11292601 | 0.84 | KMT2A (0.64) | KMT2AMEN1CA2CA1CA9 | |
| SCHEMBL14058829 | 0.83 | KMT2A (0.58) | KMT2AMEN1CA2CA1CA9 | |
| SCHEMBL87450 | 0.82 | CA1 (0.83) | KMT2AMEN1CA2CA1CA9 | |
| SCHEMBL9795930 | 0.82 | STS (0.70) | KMT2AMEN1CA2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118852135-A | N-acyl sulfonamide compound, preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2024-10-29 | — | — | CN | disclosed |
| EP-3426246-B1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RES INST (TW) | 2024-05-01 | — | — | EP | disclosed |
| CN-108794358-B | Substituted benzenesulfonyl compounds and application thereof in preparing medicines | 中国人民解放军第二军医大学 | 2022-08-12 | — | — | CN | disclosed |
| CN-108883099-B | Thiazolidinone compounds and use thereof | 石全 | 2021-09-28 | — | — | CN | disclosed |
| US-10544113-B2 | Thiazolidinone compounds and use thereof | NATIONAL HEALTH RESEARCH INSTITUTE (TW) | 2020-01-28 | — | — | US | disclosed |
| US-10544113-B2 | Thiazolidinone compounds and use thereof | NATIONAL HEALTH RESEARCH INSTITUTE (TW) | 2020-01-28 | — | — | US | disclosed |
| EP-3426246-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | National Health Research Institutes (TW) | 2019-01-16 | — | — | EP | disclosed |
| CN-108883099-A | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | 石全 | 2018-11-23 | — | — | CN | disclosed |
| WO-2017155910-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2017-09-14 | — | — | WO | disclosed |
| US-20170253569-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2017-09-07 | — | — | US | disclosed |
| EP-0585155-B1 | Trifluoromethylketone derivatives of peptides having HLE inhibiting activity, their preparation and pharmaceutical composition | ADIR (FR) | 1996-12-11 | — | — | EP | disclosed |
| US-5567804-A | HUMAN LEUCOCYTE ELASTASE INHIBITOR; ANTIOXIDANT | ADIR ET COMPAGNIE (FR) | 1996-10-22 | — | — | US | disclosed |
| US-5565429-A | HUMAN LEUCOCYTE ELASTASE INHIBITORS; EMPHYSEMA; ANTIARTHRITIC AGENTS; RHEUMATIC DISEASES | ADIR ET COMPAGNIE (FR) | 1996-10-15 | — | — | US | disclosed |
| EP-0680972-A1 | Trifluoromethylketone peptide derivatives, process for their preparation and pharmaceutical compositions comprising them | ADIR ET COMPAGNIE (FR) | 1995-11-08 | — | — | EP | disclosed |
| CN-1083473-A | New imidazolium compounds and pharmaceutical composition thereof | SMITHKLINE BEECHAM CORP (US) | 1994-03-09 | — | — | CN | disclosed |
| EP-0585155-A1 | Trifluoromethylketone derivatives of peptides having HLE inhibiting activity, their preparation and pharmaceutical composition | ADIR ET COMPAGNIE (FR) | 1994-03-02 | — | — | EP | disclosed |
| US-5284958-A | Acylation, cyclization of a 5-hydrazine-1H-pyrazole | FUJI PHOTO FILM CO., LTD. (JP) | 1994-02-08 | — | — | US | disclosed |
| US-5214149-A | Process for producing a 1H-pyrazolo[5,1-c]-1,2,4-triazole compound | FUJI PHOTO FILM CO., LTD. (JP) | 1993-05-25 | — | — | US | disclosed |
| US-4990523-A | Treatment of chronic inflammatory joint disease with arylsulfonamides | A. H. ROBINS COMPANY, INCORPORATED (US) | 1991-02-05 | — | — | US | disclosed |
| WO-1990015600-A2 | TREATMENT OF CHRONIC INFLAMMATORY JOINT DISEASE WITH ARYLSULFONAMIDES | A.H. ROBINS COMPANY, INCORPORATED (US) | 1990-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544113-B2 | Thiazolidinone compounds and use thereof | OPRL1, OPRD1, OPRK1 | KMT2A 3536/4885MEN1 4566/4885CA2 4192/4885 |
| US-20170253569-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | OPRL1, OPRD1, OPRK1 | KMT2A 3536/4885MEN1 4566/4885CA2 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.